Carmen Gasca-Salas1,2, Pedro Clavero1, David García-García1,2,3, José A Obeso1,2, María C Rodríguez-Oroz1,2,3. 1. Department of Neurology and Neurosurgery, Neurosciences Area, CIMA, Clínica Universidad De Navarra, University of Navarra, Pamplona, Spain. 2. Centro De Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. 3. Department of Neurology, University Hospital Donostia; Neuroscience Unit BioDonostia Research Institute, San Sebastian; Ikerbasque, Basque Foundation for Science, Bilbao, Spain.
Abstract
INTRODUCTION: Mild cognitive impairment (MCI) and visual hallucinations (VH) are common co-morbidities and risk factors for dementia in Parkinson's disease (PD). The relative value of each of them in the progression to dementia is unknown. We investigated cognitive impairment and cerebral hypometabolism in PD-MCI patients with VH (VH-positive) and without (VH-negative). METHODS: Twenty-one PD-MCI patients (12 VH-negative, nine VH-positive) and 19 controls were studied using a comprehensive neuropsychological battery and [18F]-Fluorodeoxyglucose positron emission tomography (FDG-PET). The neuropsychological assessment was repeated after 30 months. Regional FDG uptake was analyzed using statistical parametric mapping. RESULTS: VH-positive patients had lower FDG uptake bilaterally in the occipital, and parietal cortex, right temporal lobe and in the left cingulum compared with VH-negative patients. The two groups showed no significant differences in clinical characteristics and cognitive status at baseline. After 30 months of follow-up, three (25%) and four (50%) of the VH-negative and VH-positive patients, respectively, had progressed to dementia. CONCLUSION: Even in the absence of significant cognitive differences, PD-MCI patients with VH exhibit more severe cerebral hypometabolism and had a higher rate of progression to dementia than VH-negative patients, supporting the importance of VH and cerebral hypometabolism in establishing the risk of dementia in PD-MCI.
INTRODUCTION: Mild cognitive impairment (MCI) and visual hallucinations (VH) are common co-morbidities and risk factors for dementia in Parkinson's disease (PD). The relative value of each of them in the progression to dementia is unknown. We investigated cognitive impairment and cerebral hypometabolism in PD-MCIpatients with VH (VH-positive) and without (VH-negative). METHODS: Twenty-one PD-MCIpatients (12 VH-negative, nine VH-positive) and 19 controls were studied using a comprehensive neuropsychological battery and [18F]-Fluorodeoxyglucose positron emission tomography (FDG-PET). The neuropsychological assessment was repeated after 30 months. Regional FDG uptake was analyzed using statistical parametric mapping. RESULTS: VH-positive patients had lower FDG uptake bilaterally in the occipital, and parietal cortex, right temporal lobe and in the left cingulum compared with VH-negative patients. The two groups showed no significant differences in clinical characteristics and cognitive status at baseline. After 30 months of follow-up, three (25%) and four (50%) of the VH-negative and VH-positive patients, respectively, had progressed to dementia. CONCLUSION: Even in the absence of significant cognitive differences, PD-MCIpatients with VH exhibit more severe cerebral hypometabolism and had a higher rate of progression to dementia than VH-negative patients, supporting the importance of VH and cerebral hypometabolism in establishing the risk of dementia in PD-MCI.
Authors: J L Lancaster; M G Woldorff; L M Parsons; M Liotti; C S Freitas; L Rainey; P V Kochunov; D Nickerson; S A Mikiten; P T Fox Journal: Hum Brain Mapp Date: 2000-07 Impact factor: 5.038
Authors: David A Gallagher; Laura Parkkinen; Sean S O'Sullivan; Alexander Spratt; Ameet Shah; Clare C Davey; Fion D Bremner; Tamas Revesz; David R Williams; Andrew J Lees; Anette Schrag Journal: Brain Date: 2011-09-15 Impact factor: 13.501
Authors: Stewart A Factor; Michael K Scullin; Ann B Sollinger; Julia O Land; Cathy Wood-Siverio; Lavezza Zanders; Alan Freeman; Donald L Bliwise; William M McDonald; Felicia C Goldstein Journal: J Neurol Sci Date: 2014-10-23 Impact factor: 3.181
Authors: Antonio P Strafella; Nico I Bohnen; Nicola Pavese; David E Vaillancourt; Thilo van Eimeren; Marios Politis; Alessandro Tessitore; Christine Ghadery; Simon Lewis Journal: Mov Disord Clin Pract Date: 2018-10-09
Authors: Ramtin Mehraram; Luis R Peraza; Nicholas R E Murphy; Ruth A Cromarty; Sara Graziadio; John T O'Brien; Alison Killen; Sean J Colloby; Michael Firbank; Li Su; Daniel Collerton; John Paul Taylor; Marcus Kaiser Journal: Brain Date: 2022-06-30 Impact factor: 15.255
Authors: Sang Soo Cho; Antonio P Strafella; Sarah Duff-Canning; Mateusz Zurowski; Anne-Catherine Vijverman; Veronica Bruno; Camila C Aquino; Marion Criaud; Pablo M Rusjan; Sylvain Houle; Susan H Fox Journal: Mov Disord Clin Pract Date: 2017-01-23